In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Teva agrees to develop and commercialize Regeneron's fasinumab for pain

Executive Summary

In a deal worth up to $3.6bn, Regeneron Pharmaceuticals Inc. licensed Teva Pharmaceutical Industries Ltd. worldwide rights (except in selected Asian countries) to its nerve growth factor (NGF) antibody fasinumab for osteoarthritis pain (Phase III) and chronic low back pain (Phase II).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies